NOVO-NORDISK A/S-SPONS ADR (NVO)

US6701002056 - ADR

131.89  -1.15 (-0.86%)

After market: 131.82 -0.07 (-0.05%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

NOVO-NORDISK A/S-SPONS ADR

NYSE:NVO (5/17/2024, 4:18:24 PM)

After market: 131.82 -0.07 (-0.05%)

131.89

-1.15 (-0.86%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap588.37B
Shares
PE45.17
Fwd PE31.35
Dividend Yield1.06%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NVO Daily chart

Company Profile

Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

NOVO-NORDISK A/S-SPONS ADR

Novo Alle 1

Bagsvaerd 2880

P: 4544448888

CEO: Lars Fruergaard Jorgensen

Employees: 61412

Website: https://www.novonordisk.com/

NVO News

News Image3 hours ago - InvestorPlacePharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?

Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason.

News Image10 hours ago - The Motley FoolMeet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk

Could Amgen be the next stock to soar due to a GLP-1 drug?

News Imagea day ago - ChartmillShould Quality Investors Include NYSE:NVO in Their Portfolio?

Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing?

News Imagea day ago - InvestorPlace7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs

AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.

News Imagea day ago - InvestorPlacePatent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

News Image2 days ago - The Motley FoolIf You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today

Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.

NVO Twits

Here you can normally see the latest stock twits on NVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example